A5083120377- Sarcoma Diagnosis and Treatment
- Management of metastatic bone disease
- Cancer Immunotherapy and Biomarkers
- Advanced Radiotherapy Techniques
- Hepatocellular Carcinoma Treatment and Prognosis
- Head and Neck Cancer Studies
- PARP inhibition in cancer therapy
- Colorectal Cancer Treatments and Studies
- Cancer Diagnosis and Treatment
- Spine and Intervertebral Disc Pathology
- Estrogen and related hormone effects
- Renal cell carcinoma treatment
- Lung Cancer Treatments and Mutations
- Thyroid Cancer Diagnosis and Treatment
- CAR-T cell therapy research
- Medical Imaging Techniques and Applications
- Breast Cancer Treatment Studies
- Bone Tumor Diagnosis and Treatments
- Vascular Tumors and Angiosarcomas
- Lymphoma Diagnosis and Treatment
- Bone health and treatments
- Spinal Fractures and Fixation Techniques
- Cancer Treatment and Pharmacology
- Growth Hormone and Insulin-like Growth Factors
- Cutaneous lymphoproliferative disorders research
Cancer Research UK
2010-2024
CRUK Lung Cancer Centre of Excellence
2019-2024
University College London
2014-2024
London Cancer
2011-2023
Scunthorpe General Hospital
2015
Kent and Canterbury Hospital
2015
CRUK/MRC Oxford Institute for Radiation Oncology
2015
Essex County Hospital
2015
Nottingham University Hospitals NHS Trust
2015
At Bristol
2015
It is not known whether low-dose radioiodine (1.1 GBq [30 mCi]) as effective high-dose (3.7 [100 for treating patients with differentiated thyroid cancer or the effects of (especially at a low dose) are influenced by using either recombinant human thyrotropin (thyrotropin alfa) hormone withdrawal.At 29 centers in United Kingdom, we conducted randomized noninferiority trial comparing and radioiodine, each combination alfa withdrawal before ablation. Patients (age range, 16 to 80 years) had...
Initial results of the UK/ANZ DCIS (UK, Australia, and New Zealand ductal carcinoma in situ) trial suggested that radiotherapy reduced new breast events ipsilateral invasive situ (DCIS) compared with no radiotherapy, but significant effects were noted tamoxifen. Here, we report long-term this trial.Women completely locally excised recruited into a randomised 2×2 factorial tamoxifen, or both. Randomisation was independently done for each two treatments (radiotherapy tamoxifen), stratified by...
BackgroundFor many years, first-line treatment for locally advanced or metastatic soft-tissue sarcoma has been doxorubicin. This study compared gemcitabine and docetaxel versus doxorubicin as sarcoma.MethodsThe GeDDiS trial was a randomised controlled phase 3 done in 24 UK hospitals one Swiss Group Clinical Cancer Research (SAKK) hospital. Eligible patients had histologically confirmed of Trojani grade 2 3, disease progression before enrolment, no previous chemotherapy any cancer. Patients...
<h3>Importance</h3> Malignant spinal canal compression, a major complication of metastatic cancer, is managed with radiotherapy to maintain mobility and relieve pain, although there no standard regimen. <h3>Objective</h3> To evaluate whether single-fraction noninferior 5 fractions radiotherapy. <h3>Design, Setting, Participants</h3> Multicenter noninferiority randomized clinical trial conducted in 42 UK Australian centers. Eligible patients (n = 686) had cancer cord or cauda equina life...
The Cancer Research UK "Over 50s" trial compared 5 and 2 years of tamoxifen in women with early breast cancer. Results are reported after median follow-up 10 years.Between 1987 1997, 3,449 patients age 50 to 81 operable cancer who had been taking 20 mg for were randomly assigned either stop or continue an additional 3 years, if they alive recurrence free. Data on recurrences, new tumors, deaths, cardiovascular events obtained (April 2010).There 1,103 755 deaths as a result cancer, 621 (CV)...
10500 Background: Standard first-line treatment of locally advanced/metastatic soft tissue sarcoma (STS) is Dox. GemDoc has activity in STS and used relapsed after failure at least one line chemotherapy. Our aim was to compare with Dox as STS. Methods: Patients (pts) from 24 UK sites 1 Swiss site were randomised receive 6 cycles 75 mg/m2 intravenously (IV) day every 3 weeks, or Gem 675 IV days 8 Doc weeks (wks). Pts had STS, Trojani grade 2 3, disease progression prior enrolment, no...
Systematic reviews have found that luteinizing hormone-releasing hormone (LHRH) agonists are effective in treating premenopausal women with early breast cancer.We conducted long-term follow-up (median 12 years) of 2706 the Zoladex In Premenopausal Patients (ZIPP), which evaluated LHRH agonist goserelin (3.6 mg injection every 4 weeks) and tamoxifen (20 or 40 daily), given for 2 years. Women were randomly assigned to receive each therapy alone, both, neither, after primary (surgery without...
The radiotherapy or ibandronate (RIB) trial was a randomized multicenter nonblind two-arm to compare intravenous given as single infusion with single-dose for metastatic bone pain. Four hundred seventy prostate cancer patients pain who were suitable local randomly assigned (single dose, 8 Gy) of (6mg) in noninferiority trial. Pain measured using the Brief Inventory at baseline and four, eight, 12, 26, 52 weeks. response assessed World Health Organization (WHO) criteria Effective Analgesic...
LBA10004 Background: SCC is a common complication of metastatic cancer. Most pts receive RT to improve neurological function and mobility relieve pain. There no standard schedule (RT ranges from single dose 8Gy 40Gy in 20 fractions). SCORAD III was conducted show whether fraction as effective multifraction without compromising patient outcomes. Methods: Pts 43 UK 4 Australian sites were randomized (1:1) external beam spinal canal or 20Gy 5 fractions; stratified by center, ambulatory status...
Primary soft tissue sarcoma (STS) is rare, with many tumors occurring in extremities. Local management limb-sparing surgery and preoperative/postoperative radiation therapy (RT) for patients at high risk of local recurrence. We prospectively investigated late normal toxicity limb function observed after intensity modulated RT (IMRT) extremity STS.
LBA10004 The full, final text of this abstract will be available at abstracts.asco.org 2:00 PM (EDT) on Friday, June 2, 2017, and in the Annual Meeting Proceedings online supplement to 20, issue Journal Clinical Oncology. Onsite Meeting, printed Saturday edition ASCO Daily News.
There has been little change to the standard treatment for osteosarcoma (OS) over last 25 years and there is an unmet need identify new biomarkers novel therapeutic approaches if outcomes are improve. Furthermore, limited evidence on impact of OS patient-reported (PROs). ICONIC (Improving Outcomes through Collaboration in Osteosarcoma; NCT04132895) a prospective observational cohort study recruiting newly diagnosed patients across United Kingdom (UK) with matched longitudinal collection...
Abstract Background Epidermal growth factor receptor (EGFR) is a therapeutic target to which HER2/HER3 activation may contribute resistance. This Phase I/II study examined the toxicity and efficacy of high-dose pulsed AZD8931, an EGFR/HER2/HER3 inhibitor, combined with chemotherapy, in metastatic colorectal cancer (CRC). Methods Treatment-naive patients received 4-day pulses AZD8931 irinotecan/5-FU (FOLFIRI) single-arm trial. Primary endpoint for I was dose limiting (DLT); II best overall...
TPS3645 Background: The prognostic advantage of early stage deficient-MMR/MSI-High CRC is lost after relapse, so there a pressing clinical need to maximize the chance cure in stages where prevalence dMMR higher comprising approximately 12% Stage 3 and 20% 2 CRC. efficacy adjuvant checkpoint inhibition this patient group has yet be demonstrated context micrometastatic disease without supporting immune-competent microenvironment. Longitudinal studies especially neoadjuvant setting would...
We report a prospective Phase II study of efficacy and toxicity for oral treosulfan in advanced Ewing sarcoma. Twenty patients, median age 19 years (range 7–39) from five UK sites, were treated with 1 g/m 2 daily 7 days 28. Primary endpoint was objective response rate. Best stable disease one patient. All patients died progressive disease, after 6.41 months. Median progression free survival 1.8 Toxicity minimal. No activity demonstrated at this dose. Progression data should be able to used...
TPS6108 Background: Standard care for locally advanced squamous cell carcinoma of the head and neck (HNSCC) is cisplatin-based chemoradiotherapy (C-CRT). Use intensity modulated radiotherapy (IMRT) reduces toxicity to normal tissue but despite aggressive primary management many patients with high risk disease develop recurrence. The PARP-1 inhibitor olaparib inhibits DNA damage repair may potentiate anti-tumour activity C-CRT. Preclinical data demonstrate potent radio-sensitisation optimal...
TPS6091 Background: Patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) have low response rates to licensed second line therapies, including PD-1 inhibitors nivolumab pembrolizumab, represent an area of unmet clinical need. The chimeric IgG1 epithelial growth factor receptor (EGFR) monoclonal antibody cetuximab potentiates the activity radiotherapy in locally advanced HNSCC chemotherapy R/M is also modest as a single agent. Cetuximab initiates Natural Killer...
Background Transarterial chemoembolization (TACE) is the current standard of care for patients with intermediate-stage hepatocellular carcinoma (HCC) and also a treatment option liver metastases from colorectal cancer. However, TACE not curative treatment, tumor progression occurs in more than half treated. Despite advances technical refinements TACE, including introduction drug-eluting beads-TACE, clinical efficacy has been optimized, improved arterial therapies are required. Objective The...
Radiotherapy improves local tumour control in patients with soft tissue sarcoma of the extremities (STSE) but it also increases probability long-term toxicities such as fibrosis, joint stiffness and lymphoedema. The use radiation dose volume thresholds, called constraints, may potentially reduce development STSE. aim this study is to determine predictors radiotherapy-related side effects for Predicting radiotherapy response, Toxicities quality-of-life related functional outcomes (PredicT) a...
Abstract Purpose This article reports detailed quality-of-life data including preferred and actual place of care from SCORAD, the only large prospective randomized trial in metastatic spinal cord compression (MSCC). Methods SCORAD compared 2 doses radiotherapy patients with MSCC: 8 Gy single fraction 20 5 fractions. In total, 686 were randomized, whom 590 had Health-Related Quality Life (HRQoL) collected at baseline least 1 later time point. HRQoL was measured using European Organisation for...